Vikas Sinha - 25 Apr 2025 Form 4 Insider Report for Verona Pharma plc (VRNA)

Reporting relationship: Director
Issuer ticker: VRNA
Reported as of: 25 Apr 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Apr 2025, 17:17:53 UTC
Prior SEC filing: 24 Feb 2025
Next SEC filing: 29 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Andrew Fisher, Attorney-in-fact for Vikas Sinha

Key filing fact

Vikas Sinha filed Form 4 for Verona Pharma plc (VRNA) on 29 Apr 2025.

Key facts

This page summarizes Vikas Sinha's Form 4 filing for Verona Pharma plc (VRNA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 29 Apr 2025, 17:17.

Change

Previous filing in this sequence was filed on 24 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VRNA transaction Derivative

Restricted Share Units

Award

Transaction value: $0
Shares: +96,000
Change %
Price: $0.000000
Shares after: 96,000
Date: 25 Apr 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 96,000
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

Footnote F2

The RSUs vest as to 25% of the total shares on each of August 1, 2025, November 1, 2025, February 1, 2026 and May 1, 2026 subject to the Reporting Person's continued service to the Issuer on each vesting date.